A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
Anthony W. Tolcher, John Kuhn, Garry Schwartz, Amita Patnaik, Lisa A. Hammond, Ian Thompson, Howard Fingert, David Bushnell, Shazli Malik, Jeffrey Kreisberg, Elzbieta Izbicka, Leslie Smetzer, Eric K. Rowinsky
Fingerprint
Dive into the research topics of 'A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer'. Together they form a unique fingerprint.